WO2002015721A2 - Zusammensetzungen zur nahrungsmittel- und tierfutterergänzung - Google Patents
Zusammensetzungen zur nahrungsmittel- und tierfutterergänzung Download PDFInfo
- Publication number
- WO2002015721A2 WO2002015721A2 PCT/EP2001/009703 EP0109703W WO0215721A2 WO 2002015721 A2 WO2002015721 A2 WO 2002015721A2 EP 0109703 W EP0109703 W EP 0109703W WO 0215721 A2 WO0215721 A2 WO 0215721A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- algae
- spirulina
- composition according
- chlorella
- proportion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 241001465754 Metazoa Species 0.000 title abstract description 15
- 239000013589 supplement Substances 0.000 title abstract 2
- 241000195493 Cryptophyta Species 0.000 claims abstract description 87
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 60
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 58
- 229940082787 spirulina Drugs 0.000 claims abstract description 55
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims abstract description 42
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 31
- 239000000047 product Substances 0.000 claims abstract description 27
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 23
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 22
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 21
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 206010060820 Joint injury Diseases 0.000 claims abstract description 7
- 230000035876 healing Effects 0.000 claims abstract description 7
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 43
- 102000016611 Proteoglycans Human genes 0.000 claims description 23
- 108010067787 Proteoglycans Proteins 0.000 claims description 23
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 19
- 229930003268 Vitamin C Natural products 0.000 claims description 19
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 19
- 235000019154 vitamin C Nutrition 0.000 claims description 19
- 239000011718 vitamin C Substances 0.000 claims description 19
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 17
- 229960002442 glucosamine Drugs 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000006052 feed supplement Substances 0.000 claims description 9
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 5
- -1 t Species 0.000 claims description 5
- 206010007710 Cartilage injury Diseases 0.000 claims description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229940097043 glucuronic acid Drugs 0.000 claims description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- PURMPUDWXOWORS-QTBDOELSSA-N (2s,3s,4s,5r)-2,3,4-trihydroxy-6-oxo-5-sulfooxyhexanoic acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](OS(O)(=O)=O)C=O PURMPUDWXOWORS-QTBDOELSSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 3
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 claims description 3
- WHCJUIFHMJFEFZ-UIAUGNHASA-N N-acetyl-beta-D-galactosamine 4-sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O WHCJUIFHMJFEFZ-UIAUGNHASA-N 0.000 claims description 3
- WJFVEEAIYIOATH-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine 6-sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](COS(O)(=O)=O)[C@@H](O)[C@@H]1O WJFVEEAIYIOATH-FMDGEEDCSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 229920000140 heteropolymer Polymers 0.000 claims description 3
- 229920001519 homopolymer Polymers 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 150000003841 chloride salts Chemical class 0.000 claims description 2
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000006872 improvement Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 210000000845 cartilage Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000284 extract Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 210000001179 synovial fluid Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 description 6
- 229940059329 chondroitin sulfate Drugs 0.000 description 6
- 230000008407 joint function Effects 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- XHMJOUIAFHJHBW-VFUOTHLCSA-N glucosamine 6-phosphate Chemical compound N[C@H]1[C@H](O)O[C@H](COP(O)(O)=O)[C@H](O)[C@@H]1O XHMJOUIAFHJHBW-VFUOTHLCSA-N 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000237536 Mytilus edulis Species 0.000 description 4
- 210000001612 chondrocyte Anatomy 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 235000020638 mussel Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 206010047623 Vitamin C deficiency Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 150000002302 glucosamines Chemical class 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 208000010233 scurvy Diseases 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241001495180 Arthrospira Species 0.000 description 2
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000192700 Cyanobacteria Species 0.000 description 2
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023215 Joint effusion Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000005455 Monosaccharide Transport Proteins Human genes 0.000 description 2
- 108010006769 Monosaccharide Transport Proteins Proteins 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102100025193 OTU domain-containing protein 4 Human genes 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 230000003011 chondroprotective effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960002849 glucosamine sulfate Drugs 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 238000009160 phytotherapy Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000003724 spirulina extract Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FGNPLIQZJCYWLE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound OS(O)(=O)=O.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO FGNPLIQZJCYWLE-BTVCFUMJSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 240000009108 Chlorella vulgaris Species 0.000 description 1
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102100038591 Endothelial cell-selective adhesion molecule Human genes 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000004894 Glutamine-fructose-6-phosphate transaminase (isomerizing) Human genes 0.000 description 1
- 108090001031 Glutamine-fructose-6-phosphate transaminase (isomerizing) Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000976560 Hemilia Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101000882622 Homo sapiens Endothelial cell-selective adhesion molecule Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 206010061298 Mucosal haemorrhage Diseases 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 229940096055 prax Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002468 redox effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003144 traumatizing effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to edible compositions for nutritional or animal feed supplementation which contain a proportion of a product of spirulina algae and / or chlorella algae and at least one component of oligosaccharide biosynthesis and optionally a component which is capable of free Neutralize radicals.
- the invention further relates to the use of spirulina or chlorella algae or products thereof or the use of the compositions mentioned to improve joint function or for prophylaxis, alleviation of discomfort or promoting healing in joint injuries or degenerative joint diseases in mammals, including humans.
- the invention further relates to methods for producing the compositions according to the invention.
- cartilage When healthy, mammalian cartilage forms a smooth surface between the bone ends of the joints.
- the cartilage is built up by chondrocytes and consists of collagen fibers which are embedded in a matrix of proteoglycans, which mainly contain chondroitin sulfate.
- proteoglycans which mainly contain chondroitin sulfate.
- the synovia In order to reduce the friction between the cartilage surfaces, there is also a highly viscous fluid, the synovia, in the joint space.
- Hyaluronic acid is an essential component of the synovial fluid.
- Proteoglycans (also often referred to as mucopolysaccharides) form the basic structure of cartilage, bones and synovial fluid.
- Proteoglycans consist of glucosaminoglycans that are bound to a small amount of protein.
- One component of the glucosaminoglycan subunit of proteoglycans in cartilage and bone is chondroitin sulfate A and chondroitin sulfate C.
- chondroitin sulfate A is the sulfate group in position 4, in chondroitin sulfate C in position 6 of the N-acetylgalactosamine residue.
- the synovial fluid proteoglycans contain hyaluronic acid as the glucosaminoglycan subunit.
- Hyaluronic acid is a macromolecular polymer with a mass> 10 6 kDa, which is formed from glucuronic acid and N-acetylgalactose units.
- Hyaluronic acid solutions are highly viscous and have lubricating properties, which is important for the mobility of the joints.
- proteoglycans contain different sugar components, including galactose, fucose, N-acetylglucosamine, N-acetylgalactosamine, glucuronic acid, iduronic acid, N-acetylgalactosamine-4-sulfate, N-acetylglucosamine-6-sulfate, glucuronic acid-2-sulfate and N-acylate may be contained in the oligosaccharide chains (Peter Karlson, short textbook on biochemistry, Georg Thieme Verlag, Stuttgart, 1980, p. 221 ff.).
- proteoglycan biosynthesis is the intracellular availability of the amino sugar building blocks. All amino sugars are synthesized in the cell from the central precursor metabolite glucosamine-6-phosphate. This is provided by the enzymatic conversion of glutamine and fructose-6-phosphate to glucosamine-6-phosphate by the glucosamine-6-phosphate synthase. The fructose-6-phosphate required for this is branched off from the glycolysis. (Albert., L. Lehninger, Biochemie, VCH Verlagsgesellschaft, Weinheim, 1985, pp. 346 ff.).
- U.S. Patent 3,697,652 uses N-acetylglucosamine to treat degenerative wear on joints.
- Horse feed supplements used for this purpose contain, for example, low-molecular sulfur compounds (DMSO, MSM), Gelatin and / or mussel extract (Arthro GAG ® , Equistro ® ), chondroitin sulfate and / or glucosamine (Chondril ® , Equistro ® , Cosequin P ® ).
- DMSO low-molecular sulfur compounds
- MSM Gelatin and / or mussel extract
- Althro GAG ® Equistro ®
- Chodroitin sulfate and / or glucosamine Chodril ® , Equistro ® , Cosequin P ®
- the use of the sulfur-containing compounds mentioned meets concerns regarding the toxicity and side effects to be expected, in particular with long-term administration. With other compositions there is little or no effect as a prophylactic or supportive measure in the treatment of degenerative joint diseases.
- Spirulina is a blue-green, multicellular, filamentous microalgae of the class Cyanophyceae.
- Spirulina algae for example the cultivated species Spirulina platensis (Arthospira platensis), have an exceptionally high concentration of various nutrients and vital substances.
- Spirulina In contrast to most other algae or bacteria, Spirulina only has a thin cell membrane that is made up of lipids and proteoglycans. Therefore, the algae in the gastrointestinal tract of mammals can be easily digested and the biologically active substances made accessible to the body.
- Spirulina consists largely of proteins, although the high content of essential amino acids is very unusual for algae. Another special feature is the high content of vitamins, especially from the B group.
- spirulina contains important minerals such as zinc, manganese and copper and extremely high amounts of bioavailable iron (Ciferri, O., Microbiological Reviews (1983), 551-578).
- Chlorella is a blue-green algae that has a nutritional value comparable to that of Spirulina, although the protein content is slightly lower.
- the use of spirulina and chlorella algae as a dietary supplement is known and is described, for example, by Ota et al., J Appl. Phycology, 5 (1993), 235-241. In this article, therapeutic effects of spirulina algae are listed, ranging from the reduction of cholesterol content through reduced nephrotoxicity of heavy metals and environmental chemicals to protection against radioactive nuclides.
- Spirulina algae extracts have also been used in cancer treatment.
- Lisheng et al., Marine Sciences (1991), 33-38 use polysaccharides from Spirulina to inhibit the proliferation of mouse hepatoma cells.
- the incorporation of 3 H-tymidine, 3 H-uridine and H-leucine was reduced dramatically. The reduced incorporation of these marker substances indicates a reduced cell growth.
- oligosaccharides are made up of rhamnose, ribose, mannose, fructose, galactose, xylose, glucose, glucuronic and galacturonic acid units, where individual sugars can contain a sulfate group (s).
- Hayashi et al., Phytotherapy Research 7 (1993), 76-80 demonstrated that aqueous spirulina extracts also inhibit the replication of herpes simplex type 1 in HeLa cells.
- Sulfated glycolipids isolated from spirulina also have antiviral potential. For example, Gustavson et al., J National Cancer Institute 81 (16) (1989), 1254, showed that after administration of these glycolipids, T-helper cells are no longer infected by HIN-1 viruses.
- vitamin C L- (+) - ascorbic acid
- the daily vitamin C requirement Humans is 1 mg / kg body weight. Most animals produce their own needs for ascorbic acid. However, humans, primates and guinea pigs, for example, rely on external supply. Fruit, vegetables and potatoes are primarily considered as sources for daily needs; liver also contains copious amounts. The biological functions of vitamin C have not yet been fully clarified because of their diversity. It is certain that because of its redox properties it plays an important protective role in the metabolism.
- the classic vitamin C deficiency disease is scurvy. Symptoms associated with a vitamin C deficiency are also spring tiredness, loss of appetite, heart problems, increased susceptibility to infections and mucosal bleeding. There is an increased need for many infectious diseases, but also for broken bones and during pregnancy.
- An object of the present invention was to provide well-tolerated compositions for food or animal feed supplementation with advantageous effects on joint function and degenerative joint diseases in mammals.
- the present invention relates to orally administrable compositions which contain a proportion of a product of spirulina algae and / or chlorella algae and at least one component of the oligosaccharide biosynthesis of proteoglycans, and optionally a constituent which is capable of free radicals to neutralize.
- the compositions according to the invention are suitable as food supplements or animal feed supplements.
- the invention further relates to the use of spirulina algae and / or chlorella algae or of products from spirulina algae and / or chlorella algae for the production of compositions having an action which improves joint function or which has a prophylactic, symptom-relieving or healing effect in joint injuries , in particular cartilage injuries, or degenerative joint diseases in mammals including humans.
- the invention also particularly includes the use of the compositions according to the invention or their use for the preparation of edible preparations for improving joint function or for prophylaxis, alleviating symptoms or promoting healing in the case of joint injuries, in particular cartilage injuries, or degenerative joint diseases in mammals, including humans.
- compositions according to the invention obtained in this way can be administered orally and are particularly suitable as food supplements in humans, for example in people who are exposed to or are subject to heavy sporting loads, or in the elderly for the prevention of degenerative joint diseases, or for the related symptom relief and / or regeneration promotion.
- compositions are furthermore outstandingly suitable as feed supplements for breeding animals, for example as nutritional supplements for young animals, or for animals which are subject to high physical requirements, such as racing or jumping horses or racing dogs.
- compositions according to the invention achieve their joint function-preserving and chondroprotective or regenerative action on several levels, namely, among other things, they support muscle building, promote the formation of synovial fluid and advantageously regulate the body's own immune system involved in degenerative processes.
- VCAM-1 vascular cell adhesion molecule
- PECAM-1 platelet and endothelial cell adhesion molecule
- VCAM-1 vascular cell adhesion molecule
- PECAM-1 platelet and endothelial cell adhesion molecule
- compositions according to the invention start in the run-up to the traumatization of the cartilage tissue by specifically promoting the building of muscle, thereby strengthening the muscle function of the musculoskeletal system and thus preventing traumatization. If trauma already exists, regeneration is supported by the muscle-building effect.
- the muscle-building effect of the compositions according to the invention presumably results in particular from the easy digestibility of the ingredients and the above-average high proportion of usable protein as well as the high concentration of vitamins and minerals, which result from the proportion of the product from spirulina algae or from chlorella Algae is made available.
- the building block of oligosaccharide biosynthesis of proteoglycans especially through glucosamine, which stimulates cartilage formation, which also prevents injuries.
- the content of acidic spirulans in the product from spirulina algae or corresponding ingredients in the product from chlorella algae at the same time leads to an advantageous modulation of the immune system, for example by inhibiting the infiltration of leukocytes after traumatizing the cartilage .
- the advantageous effects of spirulina algae and chlorella algae or of products from spirulina and chlorella algae on joint function or in prophylaxis, alleviation of discomfort or promoting healing in the case of joint injuries or degenerative joint diseases in mammals were recognized for the first time in the context of the present inventions and described.
- the supply of metabolites of the oligosaccharide biosynthesis stimulates the formation of synovial fluid or the deterioration of the lubricating properties of the synovial fluid due to the degenerative reactions initiated in the course of the knuckle trauma Processes slowed down or even stopped by excitation of the remaining chondrocytes that produce the synovial fluid.
- compositions according to the invention presumably result, inter alia, from the fact that they address several levels of the pathogenesis of degenerative gelling disorders, which results in a surprisingly good overall effect.
- the product of spirulina algae and / or chlorella algae contained in the compositions according to the invention is preferably spray-dried spirulina algae or chlorella algae.
- the S / rw / ⁇ algae product is preferably produced from algae of the Spirulina platensis species.
- Spray-dried spirulina algae suitable in connection with the compositions according to the invention are commercially available, for example from Dainippon Inc. & Chemicals Inc., Immermannstr. 65, 40210 Düsseldorf, as Spirulina Lina Green.
- Products from spirulina algae preferred in connection with the present invention have approximately the following ingredients:
- the individual ingredients are preferably roughly composed as follows:
- Spirulin ⁇ extract or S /? / Rw / m ⁇ fractions or products suitable in connection with the present invention can be identified by means of biological tests known to the person skilled in the art, for example in the animal model of adjuvant-induced arthritis, in the method described above fractions obtained can be examined with regard to their ability to alleviate the induced symptoms or to reduce the immigration of leukocytes into the inflamed tissue.
- Spirulin ⁇ algae and their products are particularly suitable in the context of the invention due to the particularly high proportion of usable protein.
- chlorella algae and their products are particularly suitable in the context of the invention due to the particularly high proportion of usable protein.
- very good results are also achieved with chlorella algae and their products.
- the C ⁇ / ore / t ⁇ algae product contained in the compositions according to the invention is produced in a preferred embodiment from algae of the type Chlorella vulgaris (IGV GmbH, Arthur-Scheunert-Allee 40/41, 14558 Bergholz-Rehmaschine).
- compositions of the invention contain a proportion of the product of spirulina algae and / or chlorella algae in the range of a total of 0.1-990 g / kg, in particular 1-550 g / kg, preferably 200-500 g / kg of the composition.
- the building block of the oligosaccharide biosynthesis of proteoglycans which is contained in the compositions according to the invention as a further additive, is a building block of the kind used in proteoglycan biosynthesis in mammals.
- the building blocks of the oligosaccharide biosynthesis of proteoglycans according to the invention are therefore metabolic Precursor compounds of proteoglycans from the group of carbohydrates. Good results are achieved with building blocks of the oligosaccharide biosynthesis of proteoglycans, which are homopolymers or heteropolymers. Monomeric building blocks of the oligosaccharide biosynthesis of proteoglycans are particularly preferred.
- the building block can each be in polysulfated, sulfated or non-sulfated form.
- Particularly suitable building blocks for the purposes of the present invention are galactose, fucose, galactosamine, glucosamine, N-acetylglucosamine, N-acetygalactosamine, N-acetymannosamine, glucuronic acid, iduronic acid, N-acetylgalactosamine-4-sulfate, N-acetylglucosamine-6-sulfate or glucuronic acid 2-sulfate or homopolymers or heteropolymers built up from these building blocks.
- Glucosamine is particularly preferred, especially as the chloride or sulfate salt, preferably in the form of its sulfate salt, since the sulfate anion introduces an additional sulfur source, which is necessary for the biosynthesis of the proteoglycans, into the composition.
- compositions according to the invention which contain glucosamine or its sulfate salt as a building block of the oligosaccharide biosynthesis are preferably substantially or completely free of free glucose, since in the cellular uptake mechanism glucose and glucosamine can compete with one another for transport by the non-specific hexose transporter.
- the proportion of the building block of oligosaccharide biosynthesis in the composition is above the proportion of this building block in spirulina algae or chlorella algae, preferably above the proportion in spray-dried spirulina algae or chlorella algae.
- the proportion is preferably two or more times, in particular more than five times or more than ten times, higher than the corresponding proportion of the building block in spray-dried spirulina algae or chlorella algae.
- Preferred proportions of the building block in the compositions according to the invention are 0.2-500 g / kg, preferably 0.5-350 g / kg, particularly preferably 10-350 g / kg or also 110-350 g / kg of the total weight.
- glucosamine is obtained from the chitin shell of crustaceans by hydrolysis and is commercially available as the chloride or sodium sulfate salt (Buckton Scott Commodities Limited, Rochford, Essex England). Such preparations have a high degree of purity.
- compositions according to the invention preferably further contain an ingredient capable of neutralizing free radicals, i.e. has anti-oxidative properties. A separate amount of this ingredient is added to the compositions.
- Preferred as a component that is able to neutralize free radicals are vitamin C, ⁇ -carotene or vitamin E. Vitamin C is particularly preferred.
- the proportion of the component which is able to neutralize free radicals is above the proportion of this component in spirulina algae or chlorella algae, preferably above the proportion in spray-dried spirulina algae or chlorella algae.
- the proportion is preferably two or more times, in particular more than five times or more than ten times, higher than the corresponding proportion of the building block in spray-dried spirulina algae or chlorella algae.
- Preferred proportions of the building block in the compositions according to the invention are 0.2-500 g / kg, preferably 0.5-200 g / kg or 1-200 g / kg, particularly preferably 5-150 g / kg and very particularly preferably 55-60 g / kg of the composition.
- compositions according to the invention can additionally contain further constituents, such as anti-inflammatory agents, and further additives and auxiliaries known to those skilled in the art, for example pharmaceutically acceptable carriers, excipients, binders and thickeners and ballast and fillers.
- further addition of sugar should be desirable, for example for reasons of galenics or acceptance, particularly in those compositions according to the invention which contain glucosamine or its sulfate salt as a building block of oligosaccharide biosynthesis, disaccharides such as sucrose or lactose are preferred, which delay Have absorption kinetics.
- sweeteners such as saccharin or cyclamate can also be contained in the product.
- flavorings or herbal extracts can also be added to the compositions according to the invention.
- compositions according to the invention can be processed into various preparations which are readily familiar to the person skilled in the art.
- they can be processed into tablets, capsules (e.g. gelatin capsules containing the compositions) or granules.
- the temperatures are not too high.
- the conditions are preferably selected such that a temperature of 80 ° C., preferably 60 ° C., is not exceeded or is exceeded only for a short time.
- a further advantageous processing is the microencapsulation of individual components such as spirulina algae or chlorella algae or the entire mixture.
- Such methods are described in Shahidi F. et al., Grit. Rev. Food. Be. Nutr. 33 (6) (1993), 501-547, and have the advantage that unpleasant flavors do not occur, since the encapsulation is only dissolved in the gastrointestinal tract.
- suitable encapsulation materials or by further packaging the microencapsulated or non-microencapsulated mixture in capsules that only dissolve through enzymatic digestion in the intestinal tract, it is possible to prevent acid-sensitive components, such as sulfated carbohydrates, from being destroyed in the stomach.
- Packaging in gelatin capsules is an example.
- Spray-dried spirulina or chlorella algae optionally mixed with one or more of the above-mentioned building blocks of the oligosaccharide biosynthesis of proteoglycans and possibly one or more of the above-mentioned components which are able to neutralize free radicals, are preferably at room temperature into a cauldron one Blown in wet pelletizer.
- On the side of the boiler are fine nozzles, from which water with additives is sprayed out as a fine mist. The blown-in dust clumps more and more. When a certain particle size is exceeded, the particles collect in the form of granules at the bottom of the device.
- Suitable particle sizes in this regard are, for example, particles with diameters of approximately 2-3 mm.
- the wet granulation method according to the invention is particularly suitable because it is very gentle on the nutrients and vitamins in the composition.
- compositions according to the invention can also contain, for example, gelatin or starch in order to obtain rubber-like preparations.
- gelatin for example, an addition of gelatin in amounts of 4-8%, preferably 6%, is suitable.
- Such rubber-like preparations are suitable in the form of rubber bodies, for example as feed supplements for dogs and cats, and can also contain further constituents, such as meat, fish or liver extracts, in order to increase acceptance in the animals.
- the dose of administration can vary within certain suitable limits and depends on the individual and the particular purpose of administration. In humans, for example, administration amounts of 1.6 g of spray-dried spirulina algae or chlorella algae, 1 g of glucosamine and 170 mg of vitamin C are suitable, for horses, for example, 2.1 g of spray-dried spirulina algae or chlorella algae, 1 g of glucosamine and 510 mg of vitamin C (since horses do not have any significant additional sources of vitamin C in normal feed; all of the above weight data are to be understood as per 100 kg body weight per day).
- Suitable periods of administration are, for example, 5 to 10 weeks, with administration being well tolerated even over longer periods. In the first two
- compositions or the preparations based thereon according to the present invention should, if possible, be taken on an empty stomach or before meals.
- spirulina or chlorella algae or products of spirulina or chlorella algae and the compositions according to the invention based thereon for the first time it may be, for example, arthrosis, arthritis, and act on inflammation of the joints. It is clear to the person skilled in the art that, according to the invention, it can be used in the most diverse forms of arthrosis or arthritis. In the case of arthritis there is an advantageous use according to the invention, for example in rheumatoid arthritis, but also in juvenile chronic arthritis.
- Example 1 Preparation of a composition according to the invention 22.5 kg of Spirulina platensis (Arthrospira) (DIC Europe), 11 kg of glucosamine sulfate (Buckton Scott), 5.5 kg of vitamin C (Merck) and 61 kg of sucrose were used to produce a feed supplement for horses dry mixed for homogeneity. The mixture was then placed in a wet granulator. The granules obtained were then dried at 35 ° C. for 10 min and sieved.
- Example 2 Preparation of a composition according to the invention 550 g of Spirulina platensis (Arthrospira) (DIC Europe), 350 g of glucosamine sulfate (Buckton Scott), 5 g of lactose (Merck), 60 g of vitamin C (Merck) were used to prepare a human dietary supplement. 30 g Avicel PH-102 and 5 g Magnesium stearate dry mixed until homogeneous. Tablets were then pressed under conditions which ensured that a temperature of 60 ° C was not exceeded. The tablets obtained had a diameter of 10 mm and a mass of 340 mg per piece.
- composition according to Example 2 was administered to a 39-year-old male individual with beginning gonarthrosis on both sides and corresponding complaints in the knee joints.
- the symptoms typical of gonarthrosis sometimes began to sag suddenly after long periods of stress.
- the complaints in the period mentioned included recurrent pain at rest of both knee joints after high stress.
- Example 2 The composition according to Example 2 was taken over a period of one month in a dosage of 3 3 tablets per day. The symptoms disappeared after about three weeks. The subject also observed a significantly better ability to concentrate with significantly increased vigilance, as well as a significant increase in general mental and physical performance with the start of regular intake.
- composition according to Example 2 was administered to a 68-year-old male individual with advanced bilateral gonarthrosis and corresponding complaints. According to the symptoms, the symptoms that are typical of a chronic course have existed for over 40 years before the start of administration, i.e. Swelling with joint effusions and severe stress and rest pain after exercise.
- composition according to Example 2 was taken over a period of 3 months in a dosage of 3 ⁇ 3 tablets daily.
- the subject showed subjectively a generally significantly improved well-being with increased mental Balance and physical and mental resilience compared to the period before the start of taking.
- composition according to Example 2 was administered to a 71-year-old male individual diagnosed with advanced gonarthrosis.
- the subject had increasing symptoms in the area of both knee joints about 5 years before the administration date, slightly more pronounced on the right than on the left.
- the walking distance was limited to approx. 200m with considerable symptoms. Because of the pronounced pain at rest, sleep disorders occurred.
- the increasing use of anti-inflammatory drugs led to considerable gastrointestinal side effects with the formation of duodenal ulcers.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE20121186U DE20121186U1 (de) | 2000-08-22 | 2001-08-22 | Zusammensetzungen zur Nahrungsmittel- und Tierfutterergänzung |
AU2001295501A AU2001295501A1 (en) | 2000-08-22 | 2001-08-22 | Foodstuff and animal feedstuff supplement compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10041067 | 2000-08-22 | ||
DE10041067.7 | 2000-08-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002015721A2 true WO2002015721A2 (de) | 2002-02-28 |
WO2002015721A3 WO2002015721A3 (de) | 2002-06-06 |
Family
ID=7653305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/009703 WO2002015721A2 (de) | 2000-08-22 | 2001-08-22 | Zusammensetzungen zur nahrungsmittel- und tierfutterergänzung |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001295501A1 (de) |
DE (1) | DE20121186U1 (de) |
WO (1) | WO2002015721A2 (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1019135A5 (nl) * | 2010-01-08 | 2012-03-06 | Lab Smeets Nv | Voedingssupplement bevattende glucosamine. |
WO2012056008A1 (en) * | 2010-10-28 | 2012-05-03 | Jonas Nilsson | Diagnosis and treatment of alzheimer's disease |
US8198067B2 (en) | 2001-03-23 | 2012-06-12 | Advanced Bionutrtion Corporation | Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins |
EP2523564A2 (de) * | 2010-01-11 | 2012-11-21 | Shawn Paul Madere | Ernährungsergänzung zur verbesserung der abgabe zusätzlicher zielproteinfraktionen (tpf), intrazelluläre absorption und verwendung |
WO2016038175A1 (fr) * | 2014-09-11 | 2016-03-17 | Phyco- Biotech | Composition comprenant une microalgue enrichie en silicium pour une utilisation therapeutique |
CN109511651A (zh) * | 2019-01-04 | 2019-03-26 | 青岛麦迪赛斯生物科技有限公司 | 一种人脐带间充质干细胞无血清冻存液的制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004051864A1 (de) * | 2004-10-26 | 2006-04-27 | Herold, Hubert, Dr. | Zusammensetzung zur Verbesserung des Haarkleids von Säugetieren |
DE102006056454A1 (de) * | 2006-11-28 | 2008-05-29 | Bluebiotech International Gmbh | Nahrungsergänzungsmittel |
CN104642735B (zh) * | 2013-11-15 | 2018-05-22 | 中国科学院过程工程研究所 | 一种饲料用复合糖制剂及含其饲料和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585365A (en) * | 1993-07-27 | 1996-12-17 | Nippon Oil Co., Ltd. | Antiviral polysaccharide |
US5709855A (en) * | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
RU2137402C1 (ru) * | 1998-02-03 | 1999-09-20 | Товарищество с ограниченной ответственностью "Биосоляр МГУ" | Пищевая добавка |
WO2002011746A2 (en) * | 2000-08-10 | 2002-02-14 | Ocean Nutrition Canada Limited | Chlorella preparations exhibiting immunomodulating properties |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5521715A (en) * | 1978-07-31 | 1980-02-16 | Mitsuo Tateyama | Chlorella-containing powder and its preparation |
JPS61167620A (ja) * | 1985-01-19 | 1986-07-29 | Toa Nenryo Kogyo Kk | 多糖類を含んで成る抗癌剤 |
CN1117800A (zh) * | 1994-09-01 | 1996-03-06 | 深圳天赐福科技有限公司 | 清除烟毒型保健食品 |
JPH0967265A (ja) * | 1995-08-31 | 1997-03-11 | Nippon Oil Co Ltd | 魚類病原ウイルスに対する抗ウイルス剤 |
-
2001
- 2001-08-22 WO PCT/EP2001/009703 patent/WO2002015721A2/de active Application Filing
- 2001-08-22 DE DE20121186U patent/DE20121186U1/de not_active Expired - Lifetime
- 2001-08-22 AU AU2001295501A patent/AU2001295501A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585365A (en) * | 1993-07-27 | 1996-12-17 | Nippon Oil Co., Ltd. | Antiviral polysaccharide |
US5709855A (en) * | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
RU2137402C1 (ru) * | 1998-02-03 | 1999-09-20 | Товарищество с ограниченной ответственностью "Биосоляр МГУ" | Пищевая добавка |
WO2002011746A2 (en) * | 2000-08-10 | 2002-02-14 | Ocean Nutrition Canada Limited | Chlorella preparations exhibiting immunomodulating properties |
Non-Patent Citations (7)
Title |
---|
DATABASE WPI Section Ch, Week 199743 Derwent Publications Ltd., London, GB; Class B04, AN 1997-457996 XP002195087 & CN 1 117 800 A (TIANCIFU SCI & TECHNOLOGY CO LTD SHENZHE), 6. März 1996 (1996-03-06) * |
DAVIS R H ET AL: "VITAMIN C INFLUENCE ON LOCALIZED ADJUVANT ARTHRITIS" JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, E ASSOCIATION, WASHINGTON, DC,, TH, Bd. 80, Nr. 8, 1990, Seiten 414-418, XP001055555 ISSN: 8750-7315 * |
HAYASHI T ET AL: "CALCIUM SPIRULAN, AND INHIBITOR OF ENVELOPED VIRUS REPLICATION, FROM A BLUE-GREEN ALGA SPIRULINA PLATENSIS" JOURNAL OF NATURAL PRODUCTS, XX, XX, Bd. 59, Nr. 1, 1996, Seiten 83-87, XP001055143 ISSN: 0163-3864 in der Anmeldung erw{hnt * |
PATENT ABSTRACTS OF JAPAN vol. 004, no. 050 (C-007), 16. April 1980 (1980-04-16) -& JP 55 021715 A (TATEYAMA MITSUO), 16. Februar 1980 (1980-02-16) * |
PATENT ABSTRACTS OF JAPAN vol. 010, no. 373 (C-391), 12. Dezember 1986 (1986-12-12) -& JP 61 167620 A (TOA NENRYO KOGYO KK), 29. Juli 1986 (1986-07-29) * |
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 07, 31. Juli 1997 (1997-07-31) -& JP 09 067265 A (NIPPON OIL CO LTD), 11. März 1997 (1997-03-11) * |
SCHWARTZ E R ET AL: "PROTEOGLYCAN STRUCTURE AND METABOLISM IN NORMAL AND OSTEOARTHRITIC CARTILAGE OF GUINEA PIGS" ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, Bd. 24, Nr. 12, Dezember 1981 (1981-12), Seiten 1528-1539, XP001004732 ISSN: 0004-3591 in der Anmeldung erw{hnt * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198067B2 (en) | 2001-03-23 | 2012-06-12 | Advanced Bionutrtion Corporation | Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins |
BE1019135A5 (nl) * | 2010-01-08 | 2012-03-06 | Lab Smeets Nv | Voedingssupplement bevattende glucosamine. |
EP2523564A2 (de) * | 2010-01-11 | 2012-11-21 | Shawn Paul Madere | Ernährungsergänzung zur verbesserung der abgabe zusätzlicher zielproteinfraktionen (tpf), intrazelluläre absorption und verwendung |
EP2523564A4 (de) * | 2010-01-11 | 2013-11-13 | Shawn Paul Madere | Ernährungsergänzung zur verbesserung der abgabe zusätzlicher zielproteinfraktionen (tpf), intrazelluläre absorption und verwendung |
WO2012056008A1 (en) * | 2010-10-28 | 2012-05-03 | Jonas Nilsson | Diagnosis and treatment of alzheimer's disease |
US8916387B2 (en) | 2010-10-28 | 2014-12-23 | Jonas Nilsson | Diagnosis and treatment of Alzheimer's disease |
WO2016038175A1 (fr) * | 2014-09-11 | 2016-03-17 | Phyco- Biotech | Composition comprenant une microalgue enrichie en silicium pour une utilisation therapeutique |
FR3025721A1 (fr) * | 2014-09-11 | 2016-03-18 | Phyco Biotech | Composition comprenant une microalgue enrichie en silicium pour une utilisation therapeutique |
CN109511651A (zh) * | 2019-01-04 | 2019-03-26 | 青岛麦迪赛斯生物科技有限公司 | 一种人脐带间充质干细胞无血清冻存液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
DE20121186U1 (de) | 2002-05-02 |
WO2002015721A3 (de) | 2002-06-06 |
AU2001295501A1 (en) | 2002-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60103066T2 (de) | Chlorella zubereitungen mit immunmodulatorischen eigenschaften | |
Bui et al. | Influence of green lipped mussels (Perna canaliculus) in alleviating signs of arthritis in dogs | |
DE102008036954B4 (de) | Verwendung einer Aminozucker enthaltenden Zusammensetzung | |
DE60034667T2 (de) | Pharmazeutische zusammensetzung aus komplexen kohlenhydraten und deren anwendung | |
KR20020019893A (ko) | 애완 동물의 관절 건강 유지 및 관절염 증상 완화용 애완동물 식품 | |
JP2010159240A (ja) | 哺乳動物のための組織・細胞障害修復能及び体内浄化能を有する組成物。 | |
DE102006056454A1 (de) | Nahrungsergänzungsmittel | |
DE69820053T2 (de) | Stör-notokord zur verminderung der symptome / behandlung von arthritis | |
KR100973192B1 (ko) | 노령견의 관절염 개선용 기능성 사료 조성물 | |
WO2002015721A2 (de) | Zusammensetzungen zur nahrungsmittel- und tierfutterergänzung | |
DE60002484T2 (de) | Zusammensetzung die einen alpha-amylase inhibitor und mindestens eine physiologisch akzeptabele komponente, der die intestinale absorption von "fast sugars" reduzieren kann, enthält | |
WO2017086608A1 (ko) | 수용성 이온화칼슘 및 프락토올리고당 복합제를 유효성분으로 포함하는 골질환 및 관절 질환의 예방 또는 치료용 조성물 | |
DE69031694T3 (de) | Glutamin zur Behandlung von beeinträchtigten Abwehrkräften | |
DE60311595T2 (de) | Zusammensetzung zur behandlung von gastrointestinalen beschwerden | |
KR20080009695A (ko) | 연골대사 이상질환 개선용 건강식품 및 의약품 조성물 | |
US6024959A (en) | Pharmaceutical composition containing pectin and a phospholipid used as an antidiarrheal and antiulcer agent | |
EP3381457B1 (de) | Physiologisch aktive zubereitung umfassend n-acetyl-glukosamin zur behandlung von rückenschmerzen | |
DE202007008818U1 (de) | Zusammensetzung zur Behandlung von Infekten | |
WO2011013999A9 (ko) | 키토올리고당을 함유하는 피로회복용 조성물 | |
DE60037197T2 (de) | Verwendung funktioneller oraler präparate | |
DE19838794A1 (de) | Zusammensetzung zur Behandlung von Osteoarthritis und zur nutritiven Behandlung des Gelenkknorpels | |
AT13888U1 (de) | Zusatzstoff zu Futtermitteln, Nahrungsmitteln, Trinkwasser oder pharmazeutischen Präparaten | |
RU2723888C1 (ru) | Способ применения смеси из растительного и минерального сырья при групповой дегельминтизации молодняка северных оленей в сочетании с эффективными антигельминтными препаратами | |
WO2002069984A2 (de) | Verwendung von hyaluronsäure-uroniden zur behandlung von entzündlichen vorgängen | |
Cowsert | Biological activities of acemannan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: FESTSTELLUNG EINES RECHTSVERLUSTES NACH REGEL 69(1) EPUE (EPO FORM 1205A VOM 16.06.2003) |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |